Prostatype Genomics AB (publ) (STO:PROGEN)
Sweden · Delayed Price · Currency is SEK 0.1220
+0.0065 (5.63%)
Sep 25, 2026, 5:29 PM CET
Prostatype Genomics AB Market Cap
Prostatype Genomics AB has a market cap or net worth of 68.33 million as of September 25, 2026. Its market cap has increased by 96.34% in one year.
Market Cap
68.33M
Enterprise Value
67.94M
Revenue
805.00K
Ranking
n/a
PE Ratio
n/a
Stock Price
0.12
ChartMarket Cap Chart
Since November 3, 2020, Prostatype Genomics AB's market cap has decreased from 92.30M to 68.33M, a decrease of -25.97%. That is a compound annual growth rate of -4.97%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 25, 2026 | 68.33M | 284.82% |
| Dec 30, 2025 | 17.76M | -76.14% |
| Dec 30, 2024 | 74.42M | 555.78% |
| Dec 29, 2023 | 11.35M | -76.58% |
| Dec 30, 2022 | 48.46M | -64.07% |
| Dec 30, 2021 | 134.89M | -28.46% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Nov 3, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Swedish Orphan Biovitrum AB | 151.73B |
| Getinge AB | 66.19B |
| Sectra AB | 53.56B |
| Medicover AB | 39.29B |
| Spago Nanomedical AB | 76.64M |
| Neem's Hill AB | 73.40M |
| Newbury Pharmaceuticals AB | 69.92M |
| Annexin Pharmaceuticals AB | 65.65M |